Oncotarget

Research Papers:

In vitro and in vivo effects of suloctidil on growth and biofilm formation of the opportunistic fungus Candida albicans

Beini Zeng, Jiachen Li, Yajie Wang, Pengxiang Chen, Xiaohong Wang, Jianfeng Cui, Lidong Liu, Xiaoyan Hu, Qian Cao, Ying Xiao, Junlu Dong, Yundong Sun and Yabin Zhou _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:69972-69982. https://doi.org/10.18632/oncotarget.19542

Metrics: PDF 2039 views  |   HTML 2533 views  |   ?  


Abstract

Beini Zeng1, Jiachen Li1, Yajie Wang1, Pengxiang Chen2, Xiaohong Wang1, Jianfeng Cui3, Lidong Liu4, Xiaoyan Hu1, Qian Cao1, Ying Xiao1, Junlu Dong5, Yundong Sun1 and Yabin Zhou1

1Department of Pathogenic Biology and Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People’s Republic of China

2Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, People's Republic of China

3Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, People's Republic of China

4Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, People's Republic of China

5Department of Neurobiology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People’s Republic of China

Correspondence to:

Yabin Zhou, email: [email protected]

Yundong Sun, email: [email protected]

Keywords: C. albicans, biofilm, suloctidil, virulence, vaginal candidiasis

Received: December 22, 2016     Accepted: June 19, 2017     Published: July 25, 2017

ABSTRACT

As the most frequent fungal pathogen in humans, Candida albicans can develop serious drug resistance because its biofilms are resistant to most antifungal agents; this leads to an urgent need to develop novel antifungals. Here, we evaluated the efficacy of an antithrombotic drug, suloctidil, against C. albicans biofilms in vitro and in vivo. We found that suloctidil is effective to inhibit C. albicans biofilm, with a minimum inhibitory concentration (MIC80) of 4 μg/mL, a biofilm inhibiting concentration (BIC80) of 16 μg/mL and a biofilm eradicating concentration (BEC80) of 64 μg/mL. Furthermore, the concentration-dependent characteristics of suloctidil were shown by its time-kill curves. Scanning electron microscopy images clearly revealed the morphological effects of suloctidil on biofilm. Yeast-to-hyphal form switching is a key virulence factor of C. albicans; therefore, we performed hyphal growth tests and observed that suloctidil inhibited yeast-to-hyphal form switching. This result was consistent with the down-regulation of hypha-specific gene (HWP1, ALS3, and ECE1) expression levels after suloctidil treatment. In vivo, 256 μg/mL of suloctidil significantly reduced fungal counts (P<0.01) compared to that in groups without treatment; the treatment group induced a slight histological reaction, especially when the treatment lasted for 5 days (P<0.01). Taken together, our data suggest that suloctidil is a potential antifungal agent.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19542